13,14-Dihydro-15-keto-20-ethyl prostaglandin F2alpha isopropyl ester

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 13,14-Dihydro-15-keto-20-ethyl prostaglandin F2alpha isopropyl ester
• 英文别名: propan-2-yl 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoate
• 化学式: C₂₅H₄₄O₅
• 分子量: 424.6
• InChiKey: XXUPXHKCPIKWLR-JLLPCOHGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Prostaglandins of the F series
  申请人：Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo

  公开号：EP0289349A1

  公开（公告）日：1988-11-02

  The present invention provides new compounds, 13,14-dihydro-15-keto-PGFs, and vassopressors containing them, which raise blood pressure without substantial ephemeral depression of blood pressure, trachea or enteron contraction effect inherent in usual PGFs.

  本发明提供了新的化合物 13,14-二氢-15-酮-PGFs，以及含有这些化合物的血管加压剂，它们能使血压升高，而不会产生通常的 PGFs 所固有的对血压、气管或肠道收缩的实质性短暂抑制作用。
• REMEDIAL COMPOSITION FOR INTRAOCULAR HYPERTENSION OR GLAUCOMA
  申请人：R-Tech Ueno, Ltd.

  公开号：EP0979652A1

  公开（公告）日：2000-02-16

  Combined administration of isopropyl unoprostone and Latanoprost enhances their ocular hypotensive effect synergistically.

  异丙基异前列通和拉坦前列素联合用药可协同增强降眼压作用。
• DRUG COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION OR GLAUCOMA
  申请人：Sucampo AG

  公开号：EP1142576B1

  公开（公告）日：2005-03-02
• COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS
  申请人：Mastronardi Fabrizio G.

  公开号：US20130309330A1

  公开（公告）日：2013-11-21

  The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).
• COMPOSITIONS AND METHODS FOR TREATING NAILS, CLAWS, AND HOOFS
  申请人：TOPICAL SOLUTIONS, INC.

  公开号：US20160128926A1

  公开（公告）日：2016-05-12

  The present approach relates to compositions and methods for treating fingernails, toenails, hoofs, claws and the like, in mammals. More particularly, the present approach relates to compositions and methods including a prostaglandin analog active ingredient and a carrier. The compositions and methods may be used for increasing the thickness, strength, integrity, length and/or growth rate of human nails, or both, and promoting healthy nail growth and appearance, as well as relates to compositions and methods for increasing the thickness or strength of horny parts of mammals, and promoting healthy nail, claw and hoof growth.